Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ultralife (ULBI) Research & Development (2016 - 2025)

Ultralife has reported Research & Development over the past 16 years, most recently at $2.8 million for Q4 2025.

  • Quarterly results put Research & Development at $2.8 million for Q4 2025, up 16.86% from a year ago — trailing twelve months through Dec 2025 was $10.4 million (up 25.76% YoY), and the annual figure for FY2025 was $10.4 million, up 25.76%.
  • Research & Development for Q4 2025 was $2.8 million at Ultralife, down from $2.9 million in the prior quarter.
  • Over the last five years, Research & Development for ULBI hit a ceiling of $2.9 million in Q3 2025 and a floor of $1.6 million in Q4 2021.
  • Median Research & Development over the past 5 years was $1.9 million (2023), compared with a mean of $2.0 million.
  • Biggest five-year swings in Research & Development: surged 45.33% in 2021 and later decreased 13.58% in 2024.
  • Ultralife's Research & Development stood at $1.6 million in 2021, then grew by 18.28% to $1.9 million in 2022, then fell by 2.32% to $1.9 million in 2023, then soared by 30.35% to $2.4 million in 2024, then grew by 16.86% to $2.8 million in 2025.
  • The last three reported values for Research & Development were $2.8 million (Q4 2025), $2.9 million (Q3 2025), and $2.3 million (Q2 2025) per Business Quant data.